"ACP Recommends Less-Intensive Hba1c Target For T2D" - Jeff Minerd
The ACP recommendation to de-escalate therapy in patients who achieve HbA1c levels less than 6.5 percent is notably different from other guidelines, said David W. Lam, MD, assistant professor of medicine, endocrinology, diabetes, and bone disease at the Icahn School of Medicine at Mount Sinai, in a statement. "This may change how some providers care for patients who are able to achieve this level of control. However, it is important to also consider what potential impact the subsequent increase in HbA1C level may have on the patient's quality of life and their perception of overall health."
- David W. Lam, MD, Assistant Professor, Medicine, Endocrinology, Diabetes, Bone Disease, Icahn School of Medicine at Mount Sinai
Additional Coverage: